Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

MRD Monitoring in Multiple Myeloma

July 17th 2020

The Role of Transplant in Multiple Myeloma

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

July 17th 2020

Transplant-Ineligible Multiple Myeloma

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

July 17th 2020

FDA Panel Supports Belantamab Mafodotin for Relapsed/Refractory Myeloma

July 14th 2020

The FDA’s Oncologic Drugs Advisory Committee voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.

Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma

July 14th 2020

Noopur S. Raje, MD, discusses the design of the randomized phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Dr. Costa on the Design of a First-in-Human Study With CC-93269 in R/R Myeloma

July 13th 2020

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.